Table 1.
Baseline characteristics of patients in the training and validation cohort
| Training cohort () | Validation cohort () | p | |
|---|---|---|---|
| Age (years) | 61.32 ± 12.01 | 60.63 ± 11.02 | 0.382 |
| Sex | 0.089 | ||
| Female | 238 (48.87%) | 165 (42.86%) | |
| Male | 249 (51.13%) | 220 (57.14%) | |
| Location | 0.201 | ||
| Stomach | 298 (61.19%) | 258 (67.01%) | |
| Duodenum | 45 (9.24%) | 38 (9.87%) | |
| Small intestine | 100 (20.53%) | 63 (16.36%) | |
| Others | 44 (9.03%) | 26 (6.75%) | |
| Gene mutation | |||
| KIT 9 | 40 (8.21%) | 32 (8.31%) | 1.000 |
| KIT 11 | 378 (77.62%) | 275 (71.43%) | 0.044 |
| KIT 13 | 13 (2.67%) | 10 (2.60%) | 1.000 |
| KIT 17 | 6 (1.23%) | 7 (1.82%) | 0.669 |
| PDGFRA 12 | 6 (1.23%) | 0 (0.00%) | 0.037 |
| PDGFRA 18 | 28 (5.75%) | 23 (5.97%) | 1.000 |
| Wildtype | 22 (4.52%) | 46 (11.95%) | < 0.001 |